TISIDB

Summary
Symbol	EGR2
Name	early growth response 2
Aliases	Krox-20 homolog, Drosophila; KROX20; early growth response 2 (Krox-20 homolog, Drosophila); AT591; CMT1D; KR ......
Chromosomal Location	10q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus.
Domain	PF11928 Domain of unknown function (DUF3446)
Function	Sequence-specific DNA-binding transcription factor. Binds to two specific DNA sites located in the promoter region of HOXA4. ; FUNCTION: E3 SUMO-protein ligase helping SUMO1 conjugation to its coregulators NAB1 and NAB2, whose sumoylation down-regulates EGR2 own transcriptional activity.

> Gene Ontology [ TOP ]
Biological Process	GO:0001503 ossification GO:0003002 regionalization GO:0006611 protein export from nucleus GO:0006913 nucleocytoplasmic transport GO:0007272 ensheathment of neurons GO:0007389 pattern specification process GO:0007409 axonogenesis GO:0007411 axon guidance GO:0007422 peripheral nervous system development GO:0007517 muscle organ development GO:0007519 skeletal muscle tissue development GO:0007611 learning or memory GO:0007622 rhythmic behavior GO:0008045 motor neuron axon guidance GO:0008366 axon ensheathment GO:0010001 glial cell differentiation GO:0014037 Schwann cell differentiation GO:0014706 striated muscle tissue development GO:0016925 protein sumoylation GO:0018205 peptidyl-lysine modification GO:0021545 cranial nerve development GO:0021546 rhombomere development GO:0021561 facial nerve development GO:0021569 rhombomere 3 development GO:0021571 rhombomere 5 development GO:0021593 rhombomere morphogenesis GO:0021594 rhombomere formation GO:0021602 cranial nerve morphogenesis GO:0021604 cranial nerve structural organization GO:0021610 facial nerve morphogenesis GO:0021612 facial nerve structural organization GO:0021658 rhombomere 3 morphogenesis GO:0021660 rhombomere 3 formation GO:0021664 rhombomere 5 morphogenesis GO:0021666 rhombomere 5 formation GO:0021675 nerve development GO:0021783 preganglionic parasympathetic fiber development GO:0030278 regulation of ossification GO:0030902 hindbrain development GO:0032868 response to insulin GO:0035282 segmentation GO:0035283 central nervous system segmentation GO:0035284 brain segmentation GO:0035914 skeletal muscle cell differentiation GO:0042063 gliogenesis GO:0042552 myelination GO:0043434 response to peptide hormone GO:0044708 single-organism behavior GO:0045444 fat cell differentiation GO:0048167 regulation of synaptic plasticity GO:0048168 regulation of neuronal synaptic plasticity GO:0048483 autonomic nervous system development GO:0048486 parasympathetic nervous system development GO:0048511 rhythmic process GO:0048532 anatomical structure arrangement GO:0048667 cell morphogenesis involved in neuron differentiation GO:0050804 modulation of synaptic transmission GO:0050890 cognition GO:0051168 nuclear export GO:0051169 nuclear transport GO:0060537 muscle tissue development GO:0060538 skeletal muscle organ development GO:0061564 axon development GO:0097485 neuron projection guidance GO:1901652 response to peptide
Molecular Function	GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0000987 core promoter proximal region sequence-specific DNA binding GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001085 RNA polymerase II transcription factor binding GO:0001102 RNA polymerase II activating transcription factor binding GO:0001159 core promoter proximal region DNA binding GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0003682 chromatin binding GO:0008134 transcription factor binding GO:0016874 ligase activity GO:0031625 ubiquitin protein ligase binding GO:0033613 activating transcription factor binding GO:0044389 ubiquitin-like protein ligase binding GO:0071837 HMG box domain binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-5619507: Activation of HOX genes during differentiation R-HSA-5617472: Activation of anterior HOX genes in hindbrain development during early embryogenesis R-HSA-1266738: Developmental Biology R-HSA-381340: Transcriptional regulation of white adipocyte differentiation

Summary
Symbol	EGR2
Name	early growth response 2
Aliases	Krox-20 homolog, Drosophila; KROX20; early growth response 2 (Krox-20 homolog, Drosophila); AT591; CMT1D; KR ......
Chromosomal Location	10q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between EGR2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	EGR2
Name	early growth response 2
Aliases	Krox-20 homolog, Drosophila; KROX20; early growth response 2 (Krox-20 homolog, Drosophila); AT591; CMT1D; KR ......
Chromosomal Location	10q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of EGR2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	Total # shRNA with >= 4-fold: 1	Resistant to T-cell proliferation
24476824	shRNA	melanoma	B16	Secondary screen	Total # shRNA with >= 4-fold: 5	Resistant to T-cell proliferation

Summary
Symbol	EGR2
Name	early growth response 2
Aliases	Krox-20 homolog, Drosophila; KROX20; early growth response 2 (Krox-20 homolog, Drosophila); AT591; CMT1D; KR ......
Chromosomal Location	10q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of EGR2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.801	0.0601
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.469	0.233
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.311	0.741
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.972	0.0527
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.93	0.567
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-1.015	0.651
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.069	0.883
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.145	0.896
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.222	0.844
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.409	0.0549
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	2.188	0.0307
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.356	0.11

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of EGR2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	EGR2
Name	early growth response 2
Aliases	Krox-20 homolog, Drosophila; KROX20; early growth response 2 (Krox-20 homolog, Drosophila); AT591; CMT1D; KR ......
Chromosomal Location	10q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EGR2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	EGR2
Name	early growth response 2
Aliases	Krox-20 homolog, Drosophila; KROX20; early growth response 2 (Krox-20 homolog, Drosophila); AT591; CMT1D; KR ......
Chromosomal Location	10q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EGR2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EGR2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	EGR2
Name	early growth response 2
Aliases	Krox-20 homolog, Drosophila; KROX20; early growth response 2 (Krox-20 homolog, Drosophila); AT591; CMT1D; KR ......
Chromosomal Location	10q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EGR2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	EGR2
Name	early growth response 2
Aliases	Krox-20 homolog, Drosophila; KROX20; early growth response 2 (Krox-20 homolog, Drosophila); AT591; CMT1D; KR ......
Chromosomal Location	10q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of EGR2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	EGR2
Name	early growth response 2
Aliases	Krox-20 homolog, Drosophila; KROX20; early growth response 2 (Krox-20 homolog, Drosophila); AT591; CMT1D; KR ......
Chromosomal Location	10q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between EGR2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	EGR2
Name	early growth response 2
Aliases	Krox-20 homolog, Drosophila; KROX20; early growth response 2 (Krox-20 homolog, Drosophila); AT591; CMT1D; KR ......
Chromosomal Location	10q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting EGR2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse EGR2